A paradigm use of monoclonal antibodies-conjugated nanoparticles in breast cancer treatment: current status and potential approaches

References

• Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361–370. doi: 10.1038/nrc3930.
   PubMed Web of Science ®Google Scholar
• Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9(3):34. doi: 10.3390/antib9030034.
   Web of Science ®Google Scholar
• Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016;8(8):889–906. doi: 10.2217/imt-2016-0049.
   PubMed Web of Science ®Google Scholar
• Zhang C. Hybridoma technology for the generation of monoclonal antibodies. Methods Mol Biol. 2012;901:117–135. doi: 10.1007/978-1-61779-931-0_7.
   PubMedGoogle Scholar
• Köhler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol. 1976;6(7):511–519. doi: 10.1002/eji.1830060713.
   PubMed Web of Science ®Google Scholar
• Shin SU, Morrison SL. Production and properties of chimeric antibody molecules. Methods Enzymol. 1989;178:459–476. doi: 10.1016/0076-6879(89)78034-4.
   PubMed Web of Science ®Google Scholar
• Alfaleh MA, Alsaab HO, Mahmoud AB, et al. Phage display derived monoclonal antibodies: from bench to bedside. Front Immunol. 2020;11:1986. doi: 10.3389/fimmu.2020.01986.
   PubMed Web of Science ®Google Scholar
• Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics. 2019;13:33–51. doi: 10.2147/BTT.S166310.
   PubMed Web of Science ®Google Scholar
• Kimiz-Gebologlu I, Gulce-Iz S, Biray-Avci C. Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep. 2018;45(6):2935–2940. doi: 10.1007/s11033-018-4427-x.
   PubMed Web of Science ®Google Scholar
• Posner J, Barrington P, Brier T, et al. Monoclonal antibodies: past, present and future. Handb Exp Pharmacol. 2019;260:81–141.
   PubMedGoogle Scholar
• Vahidfar N, Aghanejad A, Ahmadzadehfar H, et al. Theranostic advances in breast cancer in nuclear medicine. Int J Mol Sci. 2021;22(9):4597. doi: 10.3390/ijms22094597.
   PubMed Web of Science ®Google Scholar
• Siminzar P, Tohidkia MR, Eppard E, et al. Recent trends in diagnostic biomarkers of tumor microenvironment. Mol Imaging Biol. 2023;25(3):464–482. doi: 10.1007/s11307-022-01795-1.
   PubMed Web of Science ®Google Scholar
• Al-Taie A, Sheta N. Clinically approved monoclonal antibodies-based immunotherapy: association with glycemic control and impact role of clinical pharmacist for cancer patient care. Clin Ther. 2023;S0149-2918(23)00408-3. doi: 10.1016/j.clinthera.2023.10.016.
   Google Scholar
• Aghanejad A, Bonab SF, Sepehri M, et al. A review on targeting tumor microenvironment: the main paradigm shift in the mAb-based immunotherapy of solid tumors. Int J Biol Macromol. 2022;207:592–610. doi: 10.1016/j.ijbiomac.2022.03.057.
   PubMed Web of Science ®Google Scholar
• Buss NA, Henderson SJ, McFarlane M, et al. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012;12(5):615–622. doi: 10.1016/j.coph.2012.08.001.
   PubMed Web of Science ®Google Scholar
• Mullard A. 2018 FDA drug approvals. Nat Rev Drug Discov. 2019;18(2):85–89. doi: 10.1038/d41573-019-00014-x.
   PubMed Web of Science ®Google Scholar
• García Merino A. Monoclonal antibodies. Basic features. Neurologia. 2011;26(5):301–306. doi: 10.1016/S2173-5808(11)70063-3.
   PubMed Web of Science ®Google Scholar
• Geng X, Kong X, Hu H, et al. Research and development of therapeutic mAbs: an analysis based on pipeline projects. Hum Vaccin Immunother. 2015;11(12):2769–2776. doi: 10.1080/21645515.2015.1074362.
   PubMed Web of Science ®Google Scholar
• Breedveld FC. Therapeutic monoclonal antibodies. Lancet. 2000;355(9205):735–740. doi: 10.1016/s0140-6736(00)01034-5.
   PubMed Web of Science ®Google Scholar
• Hinke SA, Cieniewicz AM, Kirchner T, et al. Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody. Mol Metab. 2018;10:87–99. doi: 10.1016/j.molmet.2018.01.014.
   PubMed Web of Science ®Google Scholar
• Parakh S, King D, Gan HK, et al. Current development of monoclonal antibodies in cancer therapy. Recent Results Cancer Res. 2020;214:1–70.
   PubMedGoogle Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–287. doi: 10.1038/nrc3236.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Monoclonal antibodies to treat cancer; 2016. Available from: https://www.cancer.org/treatment/treatments-and-side-effects/treatmenttypes/ immunotherapy/monoclonal-antibodies.html; [cited 2019 Mar 27].
   Google Scholar
• Bayer V. An overview of monoclonal antibodies. Semin Oncol Nurs. 2019;35(5):150927. doi: 10.1016/j.soncn.2019.08.006.
   PubMed Web of Science ®Google Scholar
• Liu JK. The history of monoclonal antibody development – progress, remaining challenges and future innovations. Ann Med Surg. 2014;3(4):113–116. doi: 10.1016/j.amsu.2014.09.001.
   PubMedGoogle Scholar
• Fu Z, Li S, Han S, et al. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93.
   PubMed Web of Science ®Google Scholar
• Lin W, Kurosawa K, Murayama A, et al. B-cell display-based one-step method to generate chimeric human IgG monoclonal antibodies. Nucleic Acids Res. 2011;39(3):e14. doi: 10.1093/nar/gkq1122.
   PubMed Web of Science ®Google Scholar
• Mak TM, Hanson BJ, Tan YJ. Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza a H5N1 clades. Antiviral Res. 2014;107:76–83. doi: 10.1016/j.antiviral.2014.04.011.
   PubMed Web of Science ®Google Scholar
• Rita Costa A, Elisa Rodrigues M, Henriques M, et al. Guidelines to cell engineering for monoclonal antibody production. Eur J Pharm Biopharm. 2010;74(2):127–138. doi: 10.1016/j.ejpb.2009.10.002.
   PubMed Web of Science ®Google Scholar
• Shepard HM, Phillips GL, Thanos CD, et al. Developments in therapy with monoclonal antibodies and related proteins. Clin Med. 2017;17(3):220–232. doi: 10.7861/clinmedicine.17-3-220.
   PubMed Web of Science ®Google Scholar
• Waldmann H. Human monoclonal antibodies: the benefits of humanization. Methods Mol Biol. 2019;1904:1–10. doi: 10.1007/978-1-4939-8958-4_1.
   PubMedGoogle Scholar
• Sedykh SE, Prinz VV, Buneva VN, et al. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018;12:195–208. doi: 10.2147/DDDT.S151282.
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometr Syst Pharmacol. 2017;6(9):576–588. doi: 10.1002/psp4.12224.
   PubMedGoogle Scholar
• Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507. doi: 10.2165/11531280-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Ovacik M, Lin K. Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development. Clin Transl Sci. 2018;11(6):540–552. doi: 10.1111/cts.12567.
   PubMed Web of Science ®Google Scholar
• Baxter LT, Zhu H, Mackensen DG, et al. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994;54(6):1517–1528.
   PubMed Web of Science ®Google Scholar
• Molthoff CF, Pinedo HM, Schlüper HM, et al. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab′)2 fragments in experimental ovarian cancer. Br J Cancer. 1992;65(5):677–683. doi: 10.1038/bjc.1992.144.
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1–110. doi: 10.1159/000385919.
   PubMedGoogle Scholar
• Lammerts van Bueren JJ, Bleeker WK, Bøgh HO, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 2006;66(15):7630–7638. doi: 10.1158/0008-5472.CAN-05-4010.
   PubMed Web of Science ®Google Scholar
• Duconge J, Fernández-Sánchez E, Macías A, et al. Monoclonal anti-EGF receptor antibody (ior-R3) pharmacokinetic study in tumor bearing nude mice: role of the receptor-mediated endocytosis on drug clearance. Eur J Drug Metab Pharmacokinet. 2002;27(2):101–105. doi: 10.1007/BF03190423.
   PubMed Web of Science ®Google Scholar
• Coffey GP, Stefanich E, Palmieri S, et al. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther. 2004;310(3):896–904. doi: 10.1124/jpet.104.067611.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information; 2023 [cited 2023 Jan 19]. Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
   Google Scholar
• Drug approvals and databases; 2023 [cited 2023 Jan 11]. Available from: https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
   Google Scholar
• Human medicine European Public Assessment Report (EPAR); 2023 [cited 2023 Jan 20]. Available from: https://www.ema.europa.eu/en/medicines
   Google Scholar
• FDA; 2023 [cited 2023 Jan 20]. Available from: https://www.fdahelp.us/?gclid=Cj0KCQjwxMmhBhDJARIsANFGOStcSfEi-9kV1hdPv-cRqbNKbrXYuPnD0C9tJe88X8Pp1ENkFKJJOiwaAjBxEALw_wcB
   Google Scholar
• Dang Y, Guan J. Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med. 2020;1:10–19. doi: 10.1016/j.smaim.2020.04.001.
   PubMedGoogle Scholar
• Naeimi R, Najafi R, Molaei P, et al. Nanoparticles: the future of effective diagnosis and treatment of colorectal cancer? Eur J Pharmacol. 2022;936:175350. doi: 10.1016/j.ejphar.2022.175350.
   PubMed Web of Science ®Google Scholar
• Hashemzadeh N, Dolatkhah M, Adibkia K, et al. Recent advances in breast cancer immunotherapy: the promising impact of nanomedicines. Life Sci. 2021;271:119110. doi: 10.1016/j.lfs.2021.119110.
   PubMed Web of Science ®Google Scholar
• Foroughi-Nia B, Barar J, Memar MY, et al. Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors. Life Sci. 2021;278:119642. doi: 10.1016/j.lfs.2021.119642.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Sponchioni M, Morbidelli M, et al. Polymer nanoparticles for the intravenous delivery of anticancer drugs: the checkpoints on the road from the synthesis to clinical translation. Nanoscale. 2018;10(48):22701–22719. doi: 10.1039/c8nr05933k.
   PubMed Web of Science ®Google Scholar
• He H, Liu L, Morin EE, et al. Survey of clinical translation of cancer nanomedicines—lessons learned from successes and failures. Acc Chem Res. 2019;52(9):2445–2461. doi: 10.1021/acs.accounts.9b00228.
   PubMed Web of Science ®Google Scholar
• Wathoni N, Puluhulawa LE, Joni IM, et al. Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer. Drug Deliv. 2022;29(1):2959–2970. doi: 10.1080/10717544.2022.2120566.
   PubMed Web of Science ®Google Scholar
• Behl A, Wani ZA, Das NN, et al. Monoclonal antibodies in breast cancer: a critical appraisal. Crit Rev Oncol Hematol. 2023;183:103915. doi: 10.1016/j.critrevonc.2023.103915.
   PubMed Web of Science ®Google Scholar
• Cardoso MM, Peça IN, Roque AC. Antibody-conjugated nanoparticles for therapeutic applications. Curr Med Chem. 2012;19(19):3103–3127. doi: 10.2174/092986712800784667.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhu X, Wei Y, et al. Recent advances in targeted gene silencing and cancer therapy by nanoparticle-based delivery systems. Biomed Pharmacother. 2023;157:114065. doi: 10.1016/j.biopha.2022.114065.
   PubMed Web of Science ®Google Scholar
• Chang J, Yu B, Saltzman WM, et al. Nanoparticles as a therapeutic delivery system for skin cancer prevention and treatment. JID Innov. 2023;3(4):100197. doi: 10.1016/j.xjidi.2023.100197.
   PubMedGoogle Scholar
• Li J, Wang S, Fontana F, et al. Nanoparticles-based phototherapy systems for cancer treatment: current status and clinical potential. Bioact Mater. 2022;23:471–507.
   PubMed Web of Science ®Google Scholar
• Raza K, Kumar P, Kumar N, et al. Advances in nanomedicine for the delivery of therapeutic nucleic acids: pharmacokinetics and biodistribution of the nanoparticles. Amsterdam: Elsevier; 2017.
   Google Scholar
• Onoue S, Yamada S, Chan H. Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine. 2014;9:1025–1037.
   PubMed Web of Science ®Google Scholar
• Helmi O, Elshishiny F, Mamdouh W. Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies. Int J Biol Macromol. 2021;184:325–338. doi: 10.1016/j.ijbiomac.2021.06.014.
   PubMed Web of Science ®Google Scholar
• Kumar A, Lale SV, Aji Alex MR, et al. Folic acid and trastuzumab conjugated redox responsive random multiblock copolymeric nanocarriers for breast cancer therapy: in-vitro and in-vivo studies. Colloids Surf B Biointerfaces. 2017;149:369–378. doi: 10.1016/j.colsurfb.2016.10.044.
   PubMed Web of Science ®Google Scholar
• Lee YH, Chang DS. Fabrication, characterization, and biological evaluation of anti-HER2 indocyanine green-doxorubicin-encapsulated PEG-b-PLGA copolymeric nanoparticles for targeted photochemotherapy of breast cancer cells. Sci Rep. 2017;7(1):46688. doi: 10.1038/srep46688.
   PubMedGoogle Scholar
• Liu J, Wang P, Huang B, et al. Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody. Int J Pharm. 2022;624:121969. doi: 10.1016/j.ijpharm.2022.121969.
   PubMedGoogle Scholar
• Fathian Kolahkaj F, Derakhshandeh K, Khaleseh F, et al. Active targeting carrier for breast cancer treatment: monoclonal antibody conjugated epirubicin loaded nanoparticle. J Drug Deliv Sci Technol. 2019;53:101136. doi: 10.1016/j.jddst.2019.101136.
   Web of Science ®Google Scholar
• Niza E, Noblejas-López MDM, Bravo I, et al. Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of dasatinib in HER2+ metastatic breast cancer. Nanomaterials. 2019;9(12):1793. doi: 10.3390/nano9121793.
   Web of Science ®Google Scholar
• Dong Z, Huang Z, Li S, et al. Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. Acta Pharm Sin B. 2023;13(3):955–966. doi: 10.1016/j.apsb.2022.09.021.
   PubMed Web of Science ®Google Scholar
• Greene MK, Richards DA, Nogueira JCF, et al. Forming next-generation antibody–nanoparticle conjugates through the oriented installation of non-engineered antibody fragments. Chem Sci. 2017;9(1):79–87. doi: 10.1039/c7sc02747h.
   PubMed Web of Science ®Google Scholar
• Saqafi B, Rahbarizadeh F. Polyethyleneimine–polyethylene glycol copolymer targeted by anti-HER2 nanobody for specific delivery of transcriptionally targeted tBid containing construct. Artif Cells Nanomed Biotechnol. 2019;47(1):501–511. doi: 10.1080/21691401.2018.1549063.
   PubMed Web of Science ®Google Scholar
• Khoshtinat Nikkhoi S, Rahbarizadeh F, Ahmadvand D, et al. Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: in vitro proof-of-concept. Eur J Pharm Sci. 2018;122:42–50. doi: 10.1016/j.ejps.2018.06.019.
   PubMed Web of Science ®Google Scholar
• Lozano N, Al-Ahmady ZS, Beziere NS, et al. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent. Int J Pharm. 2015;482(1–2):2–10. doi: 10.1016/j.ijpharm.2014.10.045.
   PubMed Web of Science ®Google Scholar
• Guo C, Chen Y, Gao W, et al. Liposomal nanoparticles carrying anti-IL6R antibody to the tumour microenvironment inhibit metastasis in two molecular subtypes of breast cancer mouse models. Theranostics. 2017;7(3):775–788. doi: 10.7150/thno.17237.
   PubMed Web of Science ®Google Scholar
• Jain S, Deore SV, Ghadi R, et al. Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy. Mater Sci Eng C Mater Biol Appl. 2021;121:111832. doi: 10.1016/j.msec.2020.111832.
   PubMed Web of Science ®Google Scholar
• Souto EB, Doktorovova S, Campos JR, et al. Surface-tailored anti-HER2/neu-solid lipid nanoparticles for site-specific targeting MCF-7 and BT-474 breast cancer cells. Eur J Pharm Sci. 2019;128:27–35. doi: 10.1016/j.ejps.2018.11.022.
   PubMed Web of Science ®Google Scholar
• Pindiprolu SKSS, Krishnamurthy PT, Dev C, et al. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer. Chem Phys Lipids. 2021;235:105033. doi: 10.1016/j.chemphyslip.2020.105033.
   PubMed Web of Science ®Google Scholar
• Dziawer Ł, Majkowska-Pilip A, Gaweł D, et al. Trastuzumab-modified gold nanoparticles labeled with 211At as a prospective tool for local treatment of HER2-Positive breast cancer. Nanomaterials. 2019;9(4):632. doi: 10.3390/nano9040632.
   Web of Science ®Google Scholar
• Stuchinskaya T, Moreno M, Cook MJ, et al. Targeted photodynamic therapy of breast cancer cells using antibody–phthalocyanine–gold nanoparticle conjugates. Photochem Photobiol Sci. 2011;10(5):822–831. doi: 10.1039/c1pp05014a.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu Y, Wang S, et al. CD44-engineered mesoporous silica nanoparticles for overcoming multidrug resistance in breast cancer. Appl Surf Sci. 2015;332:308–317. doi: 10.1016/j.apsusc.2015.01.204.
   Web of Science ®Google Scholar
• Mozafarinia M, Karimi S, Farrokhnia M, et al. In vitro breast cancer targeting using trastuzumab-conjugated mesoporous silica nanoparticles: towards the new strategy for decreasing size and high drug loading capacity for drug delivery purposes in MSN synthesis. Microporous Mesoporous Mater. 2021;316:110950. doi: 10.1016/j.micromeso.2021.110950.
   Web of Science ®Google Scholar
• Ngamcherdtrakul W, Morry J, Gu S, et al. Cationic polymer modified mesoporous silica nanoparticles for targeted SiRNA delivery to HER2+ breast cancer. Adv Funct Mater. 2015;25(18):2646–2659. doi: 10.1002/adfm.201404629.
   PubMed Web of Science ®Google Scholar
• Woodman C, Vundu G, George A, et al. Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Semin Cancer Biol. 2021;69:349–364. doi: 10.1016/j.semcancer.2020.02.009.
   PubMed Web of Science ®Google Scholar
• Gowd V, Ahmad A, Tarique M, et al. Advancement of cancer immunotherapy using nanoparticles-based nanomedicine. Semin Cancer Biol. 2022;86(Pt 2):624–644. doi: 10.1016/j.semcancer.2022.03.026.
   PubMedGoogle Scholar
• Özcan Bülbül E, Üstündağ Okur N, Mısırlı D, et al. Applying quality by design approach for the determination of potent paclitaxel loaded poly(lactic acid) based implants for localized tumor drug delivery. Int J Polym Mater Polym Biomater. 2022;72(12):968–983. doi: 10.1080/00914037.2022.2067538.
   Web of Science ®Google Scholar
• Wang S, Cheng K, Chen K, et al. Nanoparticle-based medicines in clinical cancer therapy. Nano Today. 2022;45:101512. doi: 10.1016/j.nantod.2022.101512.
   Web of Science ®Google Scholar
• Cryer AM, Thorley AJ. Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacol Ther. 2019;198:189–205. doi: 10.1016/j.pharmthera.2019.02.010.
   PubMed Web of Science ®Google Scholar
• Ashton JR, Gottlin EB, Patz EFJr, et al. A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. PLOS One. 2018;13(11):e0206950. doi: 10.1371/journal.pone.0206950.
   PubMed Web of Science ®Google Scholar
• Dheyab MA, Aziz AA, Khaniabadi PM, et al. Gold nanoparticles-based photothermal therapy for breast cancer. Photodiagn Photodyn Ther. 2023;42:103312. doi: 10.1016/j.pdpdt.2023.103312.
   PubMed Web of Science ®Google Scholar
• Song Y, Zhou B, Du X, et al. Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC). Biomed Pharmacother. 2020;125:109561. doi: 10.1016/j.biopha.2019.109561.
   PubMed Web of Science ®Google Scholar
• Wu SY, Wu FG, Chen X. Antibody-incorporated nanomedicines for cancer therapy. Adv Mater. 2022;34(24):e2109210. doi: 10.1002/adma.202109210.
   PubMed Web of Science ®Google Scholar
• Marques AC, Costa PJ, Velho S, et al. Functionalizing nanoparticles with cancer-targeting antibodies: a comparison of strategies. J Control Release. 2020;320:180–200. doi: 10.1016/j.jconrel.2020.01.035.
   PubMed Web of Science ®Google Scholar
• Mundekkad D, Cho WC. Nanoparticles in clinical translation for cancer therapy. Int J Mol Sci. 2022;23(3):1685. doi: 10.3390/ijms23031685.
   PubMed Web of Science ®Google Scholar